258 related articles for article (PubMed ID: 8568811)
1. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
2. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
3. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
[TBL] [Abstract][Full Text] [Related]
4. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
Vasudevan A; Qian Y; Vogt A; Blaskovich MA; Ohkanda J; Sebti SM; Hamilton AD
J Med Chem; 1999 Apr; 42(8):1333-40. PubMed ID: 10212118
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.
Leonard DM; Shuler KR; Poulter CJ; Eaton SR; Sawyer TK; Hodges JC; Su TZ; Scholten JD; Gowan RC; Sebolt-Leopold JS; Doherty AM
J Med Chem; 1997 Jan; 40(2):192-200. PubMed ID: 9003517
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
8. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
9. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
Augeri DJ; O'Connor SJ; Janowick D; Szczepankiewicz B; Sullivan G; Larsen J; Kalvin D; Cohen J; Devine E; Zhang H; Cherian S; Saeed B; Ng SC; Rosenberg S
J Med Chem; 1998 Oct; 41(22):4288-300. PubMed ID: 9784104
[TBL] [Abstract][Full Text] [Related]
10. Farnesyl-derived inhibitors of ras farnesyl transferase.
Kang MS; Stemerick DM; Zwolshen JH; Harry BS; Sunkara PS; Harrison BL
Biochem Biophys Res Commun; 1995 Dec; 217(1):245-9. PubMed ID: 8526918
[TBL] [Abstract][Full Text] [Related]
11. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
12. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
13. Ras farnesyltransferase: a new therapeutic target.
Leonard DM
J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
[No Abstract] [Full Text] [Related]
14. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.
Yang W; Del Villar K; Urano J; Mitsuzawa H; Tamanoi F
J Cell Biochem Suppl; 1997; 27():12-9. PubMed ID: 9591188
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
17. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
18. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
Farh L; Mitchell DA; Deschenes RJ
Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential.
Tanaka R; Rubio A; Harn NK; Gernert D; Grese TA; Eishima J; Hara M; Yoda N; Ohashi R; Kuwabara T; Soga S; Akinaga S; Nara S; Kanda Y
Bioorg Med Chem; 2007 Feb; 15(3):1363-82. PubMed ID: 17127066
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
